Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2026)
Vir Biotechnology recorded quarterly EPS (Weighted Average and Diluted) of -$0.85 in Q1 2026, down 183.33% quarter-over-quarter from -$0.3 in Q4 2025, and up 3.41% year-over-year from -$0.82 in Q1 2025.
Vir Biotechnology's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.85 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 3.41% year-over-year to -$0.85; the TTM figure through Mar 2026 stood at -$3.12 (up 26.07% YoY), while the FY2025 annual figure was -$3.16, up 17.49% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.85 for Q1 2026 at Vir Biotechnology, down from -$0.3 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.85 in Q1 2022 to a low of -$1.56 in Q3 2024.
- A 5-year average of -$0.51 and a median of -$0.85 in 2026 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 391.67% in 2022 and fell as far as 226.09% in 2022.
- Vir Biotechnology's EPS (Weighted Average and Diluted) stood at -$0.75 in 2022, then retreated by 14.67% to -$0.86 in 2023, then climbed by 11.63% to -$0.76 in 2024, then soared by 60.53% to -$0.3 in 2025, then tumbled by 183.33% to -$0.85 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.85, -$0.3, and -$1.17 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -0.85 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.85 |
| Dec 31, 2025 | -0.30 |
| Sep 30, 2025 | -1.17 |
| Jun 30, 2025 | -0.80 |
| Mar 31, 2025 | -0.88 |
| Dec 31, 2024 | -0.76 |
| Sep 30, 2024 | -1.56 |
| Jun 30, 2024 | -1.02 |
| Mar 31, 2024 | -0.48 |
| Dec 31, 2023 | -0.86 |
| Sep 30, 2023 | -1.22 |
| Jun 30, 2023 | -1.45 |
| Mar 31, 2023 | -1.06 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | 1.30 |
| Jun 30, 2022 | -0.58 |
| Mar 31, 2022 | 3.85 |
| Dec 31, 2021 | 3.94 |
| Sep 30, 2021 | 0.82 |
| Jun 30, 2021 | 0.46 |
| Mar 31, 2021 | -1.32 |
| Dec 31, 2020 | -0.85 |
| Sep 30, 2020 | -0.67 |
| Jun 30, 2020 | -0.27 |